


neo-Clerodane Diterpenes from *Salvia herbacea*

Elihú Bautista, Emma Maldonado, and Alfredo Ortega*

Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán 04510, D. F., México

S Supporting Information

ABSTRACT: Chemical investigation of the aerial parts of *Salvia herbacea* led to the isolation of eight new neo-clerodane diterpenes (1–8), named tehanins A–H, and three known compounds. The structures of these compounds were determined by analysis of their spectroscopic data. Three of the new diterpenes possess a 1,8-epoxy group (1–3). This unusual structural feature was confirmed by X-ray diffraction of 1. The structure of the previously isolated 1 α ,10 α -epoxysalviarin was revised. The absolute configuration of 6 was established by X-ray diffraction analysis of its bromo derivative 6a. Cytotoxic and anti-inflammatory activities of these diterpenes were examined. None of the compounds were considered to be cytotoxic; however, compound 7 exhibited anti-inflammatory activity comparable to that of indomethacin.




Salvia is one of 224 genera in the family Lamiaceae. This subcosmopolitan genus comprises about 900 species, including some that are used for ornamental, culinary, or medicinal purposes.¹ *Salvia* species have been utilized in traditional Mexican medicine to treat dysentery, diarrhea, and insomnia and for their abortive, expectorant, and antipyretic properties.² Metabolites reported from this genus include triterpenes,³ flavonoids,⁴ sesterterpenes,⁵ and diterpenes. Diterpenes from *Salvia* are mainly abietanes and neo-clerodanes, many of them with modified skeletons.⁶ Some of these diterpenes have shown cytotoxic,⁷ antiprotozoal,⁸ and phytotoxic activities,⁹ and one of them, salvinin A, is a nonalkaloidal, naturally occurring hallucinogen and also the first non-nitrogenous κ -opioid selective agonist.¹⁰ Salvinin A was isolated from *Salvia divinorum*,¹¹ a hallucinogenic plant used by Mazatec healers in magical rites of divination. As a part of our ongoing study of diterpenes from *Salvia*, we have now investigated the aerial parts of *Salvia herbacea* Benth. (Lamiaceae, subgenus *Calosphace*), a herbaceous plant that grows on the Isthmus of Tehuantepec in Southern Mexico. Herein, we report the structural elucidation of the isolates from this plant and the results of tests of their cytotoxic and anti-inflammatory activities.

RESULTS AND DISCUSSION

Fractionation of a Me₂CO extract of aerial parts of *S. herbacea* led to the isolation of eight new diterpenes, tehanins A–H (1–8), together with the known 1(10)-dehydrosalviarin (9),¹² 1 α ,10 α -epoxysalviarin (10), previously isolated from *Salvia lineata*,¹³ and 5,6,3'-trihydroxy-7,4'-dimethoxyflavone.¹⁴ The published structure of compound 10 will be discussed.

Tehanin A (1) was isolated as colorless crystals. It has the molecular formula C₂₀H₂₀O₆, as deduced from the [M + H]⁺ ion at *m/z* 357.1330 in the HRFABMS. Its ¹³C NMR spectrum



showed 20 signals, and the IR spectrum indicated the presence of γ - and δ -lactones and a furan ring. This information together with previous studies of the chemistry of genus *Salvia* subgenus *Calosphace*^{6a} suggested that 1 had a neo-clerodane skeleton. The ¹H and ¹³C NMR spectra of 1 (Table 1) showed the presence of a tertiary methyl group (δ_{H} 1.30 s, δ_{C} 23.6, CH₃-20), a furan ring (δ_{H} 6.45, H-14; δ_{H} 7.44, H-15; δ_{H} 7.51, H-16), a 18,19- γ -lactone (δ_{C} 172.8, C-18; δ_{C} 76.3, δ_{H} 4.68, 4.10, CH₂-19), and a

Received: February 23, 2012

Published: May 11, 2012

Table 1. ^1H and ^{13}C NMR Data for Compounds 1–3 and 3a^a

position	1 ^b		2		3 ^d		3a ^e	
	δ_{H} mult. (J in Hz)	δ_{C}	δ_{H} mult. (J in Hz)	δ_{C}	δ_{H} mult. (J in Hz)	δ_{C}	δ_{H} mult. (J in Hz)	δ_{C}
1	4.49 t (5.0)	71.6 CH	4.55 ddd (8.0, 4.0, 1.0)	75.3 CH	4.54 ddd (8.0, 4.0, 1.0)	75.3 CH	4.58 m ^c	75.3 CH
2a	6.26 ddd (10.0, 5.0, 2.0)	126.6 CH	3.08 ddd (21.0, 8.0, 6.0)	31.0 CH ₂	3.06 ddd (20.5, 8.0, 6.5)	30.8 CH ₂	3.08 ddd (21.0, 8.0, 6.5)	30.7 CH ₂
2b			2.78 ddd (21.0, 2.5, 1.0)		2.70 ddd (20.5, 2.5, 1.0)		2.75 br dd (21.0, 2.5)	
3	6.10 dd (10.0, 6.0)	122.9 CH	6.88 dd (6.0, 2.5)	134.0 CH	6.88 dd (6.5, 2.5)	133.4 CH	6.90 dd (6.5, 2.5)	133.8 CH
4 β	3.00 dd (6.0, 2.0)	49.2, CH		137.1 C		137.5 C		136.9 C
5		40.3 C		41.1, C		40.2 C		40.2 C
6 α	1.87 m ^c	25.3 CH ₂	2.02 m ^c	31.6 CH ₂	2.20 br d (16.0) ^c	39.5 CH ₂	2.13 m ^c	38.9 CH ₂
6 β	2.03 m ^c		1.67 dddd (14.5, 12.0, 8.0, 1.0)		2.03 dd (16.0, 4.0) ^c		2.13 m ^c	
7 α	1.90 m ^c	25.4 CH ₂	1.91 m ^c	25.8 CH ₂		69.1 CH		68.1 CH
7 β	2.15 dd (13.0, 8.5)		2.21 dd (14.5, 8.0)		4.42 dd (8.0, 2.0)		5.49 t (4.5)	
8		82.4 C		82.2 C		81.3 C		80.4 C
9		44.8 C		44.9 C		45.0 C		45.0 C
10 α	2.06 d (5.0) ^c	46.6 CH	1.91 d (4.0) ^c	57.5 CH	1.96 d (4.0)	57.6 CH	1.99 d (4.0)	57.5 CH
11 α	2.06 m ^c	43.2 CH ₂	2.02 m ^c	43.7 CH ₂	2.10 m ^c	44.7 CH ₂	2.13 m ^c	44.4 CH ₂
11 β	2.06 m ^c		2.02 m ^c		2.04 m ^c		2.06 m ^c	
12 β	5.81 dd (11.5, 5.0)	71.7 CH	5.78 dd (12.0, 4.5)	72.0 CH	5.75 dd (12.0, 4.0)	72.3 CH	5.68 dd (12.0, 4.0)	71.6 CH
13		123.7 C		124.3 C		123.9 C		124.1 C
14	6.45 dd (2.0, 1.0)	107.8 CH	6.44 dd (2.0, 1.0)	108.4 CH	6.45 dd (2.0, 0.5)	108.3 CH	6.44 dd (2.0, 1.0)	108.3 CH
15	7.44 dd (2.0, 1.5)	143.1 CH	7.43 t (2.0)	143.8 CH	7.44 t (1.5)	143.9 CH	7.44 t (2)	143.9 CH
16	7.51 m	139.2 CH	7.49 m	139.8 CH	7.50 m	140.0 CH	7.49 m	139.9 CH
17		168.9 C		169.7 C		171.0 C		169.1 C
18		172.8 C		168.2 C		168.2 C		167.1 C
19 _{pro-R}	4.10 d (9.5)	76.3 CH ₂	4.50 d (9.5)	79.3 CH ₂	4.69 d (9.5)	80.4 CH ₂	4.57 d (9.0)	79.8 CH ₂
19 _{pro-S}	4.68 d (9.5)		4.24, dd (9.5, 1.0)		4.29 dd (9.5, 0.5)		4.30 d (9.0)	
20	1.30 s	23.6 CH ₃	1.21 s	22.9 CH ₃	1.49 s	23.3 CH ₃	1.49 s	23.5 CH ₃

^aSpectra taken in CDCl₃ at 500 MHz for ^1H and 125 MHz for ^{13}C . ^bCDCl₃–DMSO-*d*₆. ^cOverlapped signal. ^dOH signal at δ_{H} 2.95 (br s). ^eMeCO signals at δ_{H} 2.05 (s), δ_{C} 21.0 (CH₃), 168.0 (C).

17,12- δ -lactone (δ_{C} 168.9, C-17; δ_{C} 71.7, δ_{H} 5.81, CH-12). In the HMBC spectrum, the signal at δ_{H} 3.00 (dd, $J = 6.0, 2.0$ Hz) correlated with the γ -lactone carbonyl (C-18), and it was assigned to H-4. In the COSY spectrum the last proton signal showed cross-peaks with the signals at δ_{H} 6.26 (ddd, $J = 10.0, 5.0, 2.0$ Hz, H-2) and 6.10 (dd, $J = 10.0, 6.0$ Hz, H-3), indicating the presence of a double bond at C-2. The COSY spectrum also showed cross-peaks between H-2 and the signal at δ_{H} 4.49 (br t, $J = 5.0$ Hz, H-1) and between H-1 and the signal at δ_{H} 2.06 (d, $J = 5.0$ Hz, H-10). These assignments were confirmed by the HMBC correlations shown in Figure 1. The chemical shifts of H-1 and C-1 (δ_{C} 71.6) indicated an




Figure 1. Key ^1H – ^1H COSY and HMBC correlations of 1.

oxygenated function at this position. In addition, the ^{13}C NMR spectrum showed a signal for an oxygenated non-protonated carbon at δ_{C} 82.4. HMBC correlations from H₂-6, H₂-7, H₃-20, and H-10 and/or H₂-11 (superimposed signals at δ_{H} 2.06) to the last mentioned carbon signal allowed its assignment to C-8. Thus, both C-1 and C-8 were bonded to oxygenated functions. However, five of the six oxygen atoms contained in the molecular formula of 1 were part of the lactones and the furan ring; therefore the sixth one must be present as an 1,8-epoxy group. This proposal was consistent with the molecular formula of 1 (degree of unsaturation of 11). Regarding the relative configuration of 1, the H-12 coupling constants ($J_{11\alpha-12} = 11.5$ Hz, $J_{11\beta-12} = 5.0$ Hz) established its axial disposition, its NOE correlations with H-1, its β -orientation, and also the β -orientation of the 1,8-epoxy group. NOESY correlations from H₃-20 to H-7 α and H-19_{pro-S} and those of H-19_{pro-R} with H-4 and H-6 α indicated the β -orientation of H-4 and, therefore, a *cis*-fused γ -lactone. Thus, structure 1 was established for tehanin A. This structure was confirmed by X-ray diffraction analysis of 1 (Figure 2).

Tehanin B (2) was an isomer of compound 1 (C₂₀H₂₀O₆, by HRFABMS). Comparison of the NMR spectra of these compounds indicated that they differed only in the position of the double bond in ring A, which in 2 was conjugated with the γ -lactone. This was deduced from the chemical shift of the γ -lactone carbonyl of 2 (δ_{C} 168.2, C-18), as well as from the




Figure 2. ORTEP diagram (crystallographic numbering) of tehuanine A (**1**).

signals of a trisubstituted double bond (δ_{H} 6.88, dd, $J = 6.0, 2.5$ Hz, δ_{C} 134.0, CH-3; δ_{C} 137.1, C-4). In the COSY spectrum, H-3 showed cross-peaks with the protons of a methylene at δ_{H} 3.08 (ddd, $J = 21.0, 8.0, 6.0$ Hz) and 2.78 (ddd, $J = 21.0, 2.5, 1.0$ Hz), which were assigned to H-2a and H-2b, respectively. In turn H-2a correlated with a proton geminal to the 1,8-epoxy group (δ_{H} 4.55 ddd, $J = 8.0, 4.0, 1.0$ Hz, H-1). The above-mentioned was confirmed by HMBC correlations from H-1 to C-3 and C-5 (δ_{C} 41.1) and those from H-3 to C-1 (δ_{C} 75.3), C-2 (δ_{C} 31.0), C-5, and C-18. NOESY correlations from H-1 to H-2a (α -oriented), H-2b (weak), H-10, and H-12, from H-19_{pro-R} to H-6 α and H₃-20, and from H-19_{pro-S} to H-10 and H₃-20 established that tehuanine B (**2**) had the same relative configuration as compound **1**.

Tehuanine C (**3**) showed a $[M + H]^+$ ion at m/z 373.1281, which was consistent with the molecular formula $\text{C}_{20}\text{H}_{20}\text{O}_7$, indicating that **3** contained one oxygen more than **2**. The IR spectrum of **3** showed, in addition to the absorptions for γ - and

δ -lactones and a furan ring, a band indicative of an OH group at 3497 cm^{-1} . The NMR spectra of **2** and **3** were similar. The main differences were signals for an oxygenated methine in the spectra of **3** (δ_{H} 4.42, δ_{C} 69.1) instead of those of a methylene in **2**. The methine signals were attributed to CH-7 on the basis of the HMBC correlations from H-7 to C-5, C-8, and C-9 and from H₂-6 to C-7. The COSY spectrum showed a cross-peak between H-7 and a broad OH singlet at δ_{H} 2.95, thus placing the OH at C-7. The H-7 coupling constants (dd, $J = 8.0, 2.0$ Hz) indicated its equatorial disposition and, therefore, α -axial orientation of the OH. The latter was supported by preparation of the acetyl derivative **3a**. Compound **3a** exhibited a $[M + H]^+$ ion at m/z 415.1394, in agreement with the molecular formula $\text{C}_{22}\text{H}_{22}\text{O}_8$. The ^1H and ^{13}C NMR spectra of **3a** showed the presence of an acetyl group and a low-field shift of H-7. Thus, the structure of tehuanin C was established as **3**.

Tehuanine D (**4**) had the molecular formula $\text{C}_{20}\text{H}_{20}\text{O}_6$; $[M + H]^+$ at m/z 357.1335 in the HRFABMS. The ^{13}C NMR spectrum showed 20 signals, and the IR spectrum indicated the presence of an OH, γ - and δ -lactones, and a furan ring, suggesting that **4** also possessed a clerodane-type skeleton. Its ^1H and ^{13}C NMR spectra (Tables 2 and 3) showed the presence of a tertiary methyl group (δ_{H} 1.21 s, CH₃-20) and a furan ring (δ_{H} 6.47, H-14; δ_{H} 7.43, H-15; δ_{H} 7.50, H-16). The 1(10),2-diene system was deduced from the three olefinic proton signals (δ_{H} 6.11, 6.19, and 5.63), which were assigned to H-1, H-2, and H-3, respectively, on the basis of HMBC correlations. Compound **4** also possesses a 18,19- γ -lactone (δ_{C} 177.0, C-18; δ_{C} 75.8, δ_{H} 4.48 and 4.01, CH₂-19) and a 17,12- δ -lactone (δ_{C} 172.5, C-17; δ_{C} 71.2, δ_{H} 5.54, CH-12). All these structural features were the same as those of 1(10)-dehydrosalvarin (**9**),¹³ but whereas in **9** C-8 was a methine (δ_{C} 48.5, δ_{H} 2.55, CH-8), in **4** C-8 was bonded to an OH group (IR 3432 cm^{-1}). This was evident from the chemical shift of the

Table 2. ^1H NMR Data of Compounds 4–8 and 11 (500 MHz, CDCl_3)

position	4	5 ^a	6 ^c	7	8 ^d	11 ^a
1	6.11 d (6.0)	3.63 dd (4.5, 1.5)	3.55 br s	3.46 br s	3.62 br s	3.59 dd (4.5, 2.0)
2a	6.19 ddd (9.5, 6.0, 3.0)	6.29 ddd (9.5, 4.5, 3.0)	2.95 ddd (21.0, 3.0, 1.5)	2.96 ddd (21.0, 3.0, 1.0)	2.96 ddd (21.2, 3.2, 1.2)	6.28 ddd (9.5, 4.5, 3.0)
2b			2.75 ddd (21.0, 4.0, 2.5)	2.76 ddd (21.0, 4.0, 2.5)	2.76 ddd (21.2, 4.0, 2.4)	
3	5.63 ddd (9.5, 3.0, 0.5)	5.66 dt (9.5, 1.5) ^b	6.41 m ^b	6.38 ddd (4.0, 3.0, 1.0)	6.43 m	5.66 dt (9.5, 2.0) ^b
4 β	3.08 t (3.0)	2.85 br t (3.0)				2.87 br t (3.0)
6 α	1.94 dt (14.5, 3.5)	2.03 dt (14.0, 4.5)	2.41 dd (14.0, 2.0)	2.34 dt (13.5, 8.5)	2.03 m ^b	1.86 m
6 β	1.35 dddd (14.5, 14.5, 3.5, 2.0)	1.75 m ^b	1.98 ddd (14.0, 3.5, 2.0)	1.97 m ^b	1.94 m ^b	1.79 m ^b
7 α	2.03 td (13.5, 3.5)	1.95 ddd (13.5, 12.0, 4.5)		1.94 m ^b	2.03 m ^b	2.03 m
7 β	2.47 dt (13.5, 3.5)	2.65 dt (13.5, 4.5)	4.67 br dt (3.5, 2.0)	2.52 dt (14.0, 9.0)	2.60 m ^b	2.62 m ^b
8			3.07 d (3.5)		2.63 m ^b	2.60 m ^b
11 α	2.65 dd (15.5, 12.5)	2.26 dd (15.0, 12.0)	1.47 dd (13.5, 10.5)	1.60 dd (15.0, 11.5)	1.68 dd (14.8, 11.2)	1.74 dd (15.0, 10.0)
11 β	2.24 dd (15.5, 3.5)	1.77 dd (15.0, 4.5) ^b	2.14 dd (13.5, 7.0)	1.90 dd (15.0, 2.0)	2.11 dd (14.8, 3.6)	2.16 dd (15.0, 5.0) ^b
12 β	5.54 dd ((12.5, 3.5)	5.63 dd (12.0, 4.5) ^b	5.26 dd (10.5, 7.0)	5.74 dd (11.5, 2.0)	5.57 dd (11.2, 3.6)	5.76 dd (10.0, 5.0) ^b
14	6.47 ddd (2.0, 1.0, 0.5)	6.48 dd (2.0, 1.0)	6.42 dd (2.0, 1.0) ^b	6.41 dd (2.0, 1.0)	6.40 dd (1.6, 0.8)	6.39 br s
15	7.43 td (1.5, 0.5)	7.40 t (2.0)	7.45 t (2.0)	7.43 t (2.0)	7.42 t (1.6)	7.42 m
16	7.50 m	7.46 m	7.47 m	7.49 m	7.44 m	7.43 m
19 pro-R	4.48 d (8.5)	4.50 d (8.5)	5.65 d (7.0)	5.32 d (7.5)	4.58 d (8.0)	4.47 d (9.0)
19 pro-S	4.01 dd (8.5, 2.0)	4.16 dd (8.5, 2.0)	3.93 dd (7.0, 2.0)	4.02 dd (7.5, 2.0)	4.06 dd (8.0, 1.6)	4.15 dd (9.0, 1.5)
20	1.21 s	1.11 s	1.40 s	1.07 s	1.20 s	1.22 s

^aIn CDCl_3 -DMSO- d_6 . ^bOverlapped. ^c7-OH signal at δ_{H} 4.15 (br s). ^dDetermined at 400 MHz.

Table 3. ^{13}C NMR Data (δ) of Compounds 4–8 and 11 (125 MHz, CDCl_3)

position	4	5 ^a	6	7	8 ^b	11 ^a
1	120.7 CH	48.9 CH	57.3 CH	53.4 CH	55.4 CH	49.0 CH
2	124.6 CH	125.6 CH	27.2 CH ₂	27.3 CH ₂	27.2 CH ₂	125.69 CH
3	119.1 CH	125.3 CH	127.7 CH	126.2 CH	128.1 CH	125.72 CH
4	51.5 CH	51.0 CH	133.8 C	134.0 C	132.7 C	50.7 CH
5	42.1 C	42.9 C	42.7 C	41.1 C	43.2 C	43.3 C
6	32.0 CH ₂	30.0 CH ₂	33.9 CH ₂	26.3 CH ₂	27.2 CH ₂	29.3 CH ₂
7	28.0 CH ₂	27.2 CH ₂	66.0 CH	30.9 CH ₂	20.2 CH ₂	18.0 CH ₂
8	75.0 C	73.2 C	48.1 CH	74.6 C	46.9 CH	45.4 CH
9	42.1 C	41.4 C	39.5 C	41.8 C	38.2 C	36.9 C
10	139.4 C	67.6 C	63.7 C	63.9 C	64.9 C	66.7 C
11	34.4 CH ₂	34.7 CH ₂	37.5 CH ₂	40.2 CH ₂	39.3 CH ₂	38.1 CH ₂
12	71.2 CH	71.6 CH	71.2 CH	72.9 CH	71.9 CH	71.4 CH
13	124.6 C	125.8 C	123.8 C	123.9 C	125.1 C	125.1 C
14	108.5 CH	108.1 CH	108.4 CH	108.1 CH	108.2 CH	107.6 CH
15	143.8 CH	143.0 CH	144.1 CH	143.9 CH	143.8 CH	143.1 CH
16	139.9 CH	139.3 CH	139.8 CH	140.0 CH	139.5 CH	138.7 CH
17	172.5 C	171.8 C	174.2 C	176.4 C	172.2 C	170.7 C
18	177.0 C	174.6 C	168.7 C	168.8 C	168.1 C	174.3 C
19	75.8 CH ₂	71.2 CH ₂	73.1 CH ₂	75.1 CH ₂	72.5 CH ₂	70.2 CH ₂
20	26.1 CH ₃	20.0 CH ₃	23.4 CH ₃	22.7 CH ₃	26.0 CH ₃	25.3 CH ₃

^aIn CDCl_3 -DMSO-*d*₆. ^bDetermined at 100 MHz.

C-8 signal (δ_{C} 75.0) and confirmed by the HMBC correlations from H-6 β , H-7 α , H-7 β , H-11 α , H-11 β , and H₃-20 to C-8. The low-field shift of the signals for carbons in a β -position to the OH, C-7 (δ_{C} 28.0) and C-9 (δ_{C} 42.1), compared with those of compound **9** (δ_{C} 19.1, C-7; δ_{C} 37.7, C-9), supported this assumption. NOESY correlations from H-7 α to H₃-20 and H-19_{pro-R} indicated α -axial dispositions of C-19 and C-20. A NOESY correlation between H-4 and H₂-6 was observed. Molecular models showed that this correlation is possible only if H-4 is β -oriented and, therefore, in a *syn*-relationship to C-6. Consequently the γ -lactone was *cis*-fused and α -oriented. The axial disposition of H-12 was deduced from its coupling constants ($J_{11\alpha-12} = 12.5$ Hz, $J_{11\beta-12} = 3.5$ Hz), and its β -orientation from its NOE correlations to H-1 and H-11 β . The upfield shift of the signals of C-11 (δ_{C} 34.4) and C-20 (δ_{C} 26.1) of **4**, with respect to the corresponding signals of **9** (δ_{C} 40.7, C-11; δ_{C} 32.1, C-20),^{12,13} can be explained only by a γ -gauche effect of the 8-OH group, which requires α -orientation of this group. Thus, structure **4** was established for tehuainin D.

Tehuainin E (**5**) showed IR absorptions for OH (3428 cm^{-1}), γ -lactone (1757 cm^{-1}), δ -lactone (1718 cm^{-1}), and a furan ring (3150, 1504, and 875 cm^{-1}). Its molecular formula was determined by HRFABMS as $\text{C}_{20}\text{H}_{20}\text{O}_7$ ($[\text{M} + \text{H}]^+$ at m/z 373.1282). NMR data of this compound (Tables 2 and 3) were very similar to those described for a compound isolated from *S. lineata*, to which the structure 1 α ,10 α -epoxysalviarin (**10**) was assigned.¹³ This compound was also isolated in this work. The only difference between **5** and **10** was the presence of an α -oriented OH group at C-8 in **5**. This was evident from the chemical shift of C-8 (δ_{C} 73.2), as well as by the effects that this group causes on the chemical shifts of the β - (C-7, C-9) and γ -carbons (C-11, C-20) (Table 3). The NOESY correlation from H-4 to H-6 β and that from H-6 α to H-19_{pro-S}, together with those from H₃-20 to H-7 α , H-11 α , and H₂-19, indicated an α -oriented *cis*-fused γ -lactone. The β -orientation of H-12 was deduced from its NOESY correlations with H-1, H-7 β , and H-11 β . NOESY correlations from H-1 to H-2, H-11 α , H-11 β , H-12, and H₃-20 were not sufficient to determine the orientation

of the 1,10-epoxy group, since inspection of molecular models revealed that H-1 can exhibit the same NOESY interactions independent of the orientation of this group. Thus, β -orientation of the epoxy group was confirmed by an X-ray diffraction analysis of **5** (Figure 3). This analysis also confirmed the proposed structure **5** for tehuainin E.




Figure 3. ORTEP diagram of tehuainin E (**5**).

The above results and the close similarity of the ^1H and ^{13}C NMR data of **5** and **10**, especially those concerning ring A, indicated that they have the same configuration. Therefore the structure of compound **10** must be revised to 1 β ,10 β -epoxysalviarin (**11**).

The IR spectrum of tehuainin F (**6**) showed absorptions for OH, γ - and δ -lactones, a double bond, and a furan ring. The ^{13}C NMR spectrum showed 20 signals, which, in accordance with DEPT and HSQC experiments, corresponded to one methyl, four methylene, eight methine, and seven nonprotonated carbons. The HRFABMS spectrum showed a $[\text{M} + \text{H}]^+$ ion at 373.1288, consistent with the molecular formula $\text{C}_{20}\text{H}_{20}\text{O}_7$, indicating that **6** was an isomer of **5**. The ^1H and ^{13}C NMR signals confirmed the presence of a furan ring (δ_{H} 6.42, H-14; 7.45, H-15; 7.47, H-16), a 18,19- γ -lactone (δ_{C} 168.7, C-18; δ_{H}

5.65 d, $J = 7.0$ Hz; δ_{H} 3.93 dd, $J = 7.0, 2.0$ Hz, δ_{C} 73.1, CH₂-19), and a 17,12- δ -lactone (δ_{C} 71.2, δ_{H} 5.26 dd, $J = 10.5, 7.0$ Hz, H-12; δ_{C} 174.2, C-17). The signal at δ_{H} 3.07 (d, $J = 3.5$ Hz) was assigned to H-8 since, in the HMBC spectrum, it correlated with C-17, and in the COSY experiment with H-7. The chemical shift of the H-7 signal (δ_{H} 4.67) revealed an OH at C-7. The 1,10-epoxy group was deduced from the signals for C-10 (δ_{C} 63.7) and CH-1 (δ_{C} 57.3, δ_{H} 3.55). COSY cross-peaks of H-1 with H-2 β and those of H-2 α and H-2 β with the olefinic proton at δ_{H} 6.41 showed that a double bond was located at C-3 in **6** and that the γ -lactone was α,β -unsaturated. This was confirmed by the chemical shift of the lactone carbonyl (δ_{C} 168.7). The α -axial disposition of CH₃-20 and CH₂-19 was deduced from the NOESY correlations of H-11 α to H₃-20 and those of H₃-20 to H₂-19. NOESY correlations from H-12 to H-8 and H-11 β and those from H-8 to H-6 β , H-7, H-11 β , and H-12 established a β -orientation of H-8 and α -orientations of both the furan ring and the 7-OH group. The orientation of the epoxy group could not be deduced from the NOESY correlations from H-1 to H₂-2 and H-11 β ; only the weak interaction from H-1 to the α -oriented CH₃-20 seems to account for a β -epoxy group. In order to confirm this point and also to establish the absolute configuration of **6**, a single-crystal X-ray diffraction analysis of its 16-bromo derivative **6a** (NMR data in Experimental Section) was carried out. The results (Figure 4) confirmed the above-mentioned, including β -orientation of the epoxy group, and also established that tehananine F (**6**) has the configuration of a *neo*-clerodane diterpene.




Figure 4. ORTEP diagram of 16-bromotehananine F (**6a**).

Tehananine G (**7**) had the same molecular formula as **6**, and the same functional groups in the IR spectrum. The NMR spectra of both compounds were quite similar, except that **7** had a tertiary OH group at C-8, instead of the secondary 7-OH group of **6**. This was established by the chemical shift of C-8 (δ_{C} 74.6) and the HMBC correlations from H₂-6, H-7 α , H-11 β , and H₃-20 to this carbon. The NOESY correlations from H-12 to H-7 β and H-11 β indicated the α -orientation of the OH group.

The HRFABMS spectrum of tehananine H (**8**) showed a pseudomolecular ion at m/z 357.1347 (C₂₀H₂₀O₆). The IR spectrum showed absorptions typical of a furan ring, γ - and δ -lactones, and a double bond. The NMR spectra of **7** and **8** were quite similar, but compound **8** lacked the OH group of **7**. This was evident from the signals at δ_{C} 46.9 and δ_{H} 2.63, which were attributed to CH-8 on the basis of the correlations from H-6 β and H-11 β to C-8, observed in the HMBC spectrum of **8**. The

α -orientation of H-8 was deduced from its NOESY interactions with H-19_{pro-R} and H₃-20, as well as those of H-12 with H-1, H-7 β , and H11 β . The NOESY spectrum also revealed that **7** and **8** had the same relative configuration in all the other stereogenic centers common to both compounds.

Cytotoxicity of the isolated diterpenes was evaluated against six human cancer cell lines: HCT-15, MCF-7, K-562, U-251, PC-3, and SKLU-1.¹⁵ Only compound **6** showed a marginal cytotoxicity against U251 (IC₅₀ 41.86 \pm 1.4 μ M) and SKLU-1 (IC₅₀ 38.92 \pm 4.1 μ M) cell lines. The anti-inflammatory activity of compounds **4**–**9** and **11** was evaluated using the TPA-induced ear edema model.¹⁶ Compound **7** exhibited anti-inflammatory activity (IC₅₀ 0.24 μ M/ear) comparable to that of the reference compound (indomethacin). This result suggests the need of a more extensive study of the anti-inflammatory properties of compound **7**.

EXPERIMENTAL SECTION

General Experimental Procedures. Melting points (uncorrected) were determined on a Fisher-Johns apparatus. Optical rotations were measured on a Perkin-Elmer 343 polarimeter. UV spectra were recorded on a Shimadzu UV 160U spectrophotometer. IR spectra were obtained on a Bruker Tensor 27 spectrometer. 1D and 2D NMR experiments were performed on a Varian Unity Plus 500 or on a Bruker Avance III spectrometer. Chemical shifts were referred to TMS. EIMS were obtained on a JEOL JMS-AX505SHA mass spectrometer. FABMS and HRFABMS were determined on a JEOL JMS-SX102A mass spectrometer. Column chromatography (CC) assisted with vacuum was performed on silica gel 60 (Merck G) or on a bentonitic clay¹⁷ (Tonsil Mexicana). Silica gel 230–400 mesh (Macherey-Nagel) was used for flash chromatography. TLC was carried out on precoated Macherey-Nagel Sil G/UV254 plates of 0.25 thickness. X-ray crystallographic analyses were carried out on a Bruker Smart Apex CCD diffractometer with graphite-monochromated Mo K α radiation ($\lambda = 0.71073$ Å).

Plant Material. Aerial parts of *S. herbacea* were collected at Tehuantepec, Oaxaca State, México, in August 2009. A voucher specimen (MEXU-1 039 699) was deposited at the National Herbarium.

Extraction and Isolation. The dried and powered aerial parts of *S. herbacea* (4.55 kg) were extracted with Me₂CO. The extract was concentrated at reduced pressure to obtain 308 g of residue, which was defatted by partition between hexane and MeOH–H₂O, 4:1. The hexane fraction was concentrated to obtain 125 g of residue. The MeOH–H₂O fraction was concentrated to one-fifth of its volume and extracted with EtOAc. The EtOAc fraction (172 g) was submitted to CC eluted with hexane–CH₂Cl₂, 1:1 (fractions A and B), CH₂Cl₂ (fraction C), CH₂Cl₂–Me₂CO, 95:5 (fraction D), CH₂Cl₂–Me₂CO, 9:1 (fraction E), CH₂Cl₂–Me₂CO, 7:3 (fraction F), and Me₂CO (fraction G). Fraction B (53.9 g) was separated by CC on bentonitic clay¹⁷ as follows: B1 (hexane, 0.15 g); B2 (hexane–CH₂Cl₂, 1:1; 32.58 g); B3 (EtOAc, 10.88 g). Fractions B2 and B3 were combined and purified by silica gel CC eluted with hexane–EtOAc, 4:1 (B2a, 8.4 g), 3:1 (B2b, 16.5 g), and 7:3 (B2c, 8.9 g). Fraction B2b was subjected to CC eluted with hexane–Me₂CO, 4:1 and 7:3, to obtain fractions B2b1 and B2b2, respectively. Compound **4** (6.18 g) was isolated from fraction B2b1 by crystallization from Me₂CO–hexane. Fraction B2b2 (5.1 g) was a mixture of compounds **4** and **9**. This fraction was purified by CC eluted with CHCl₃–EtOAc (98:2 to 70:30). Fractions eluted with CHCl₃–EtOAc, 98:2, gave 0.93 g of **4** and 0.48 g of **9**. Fraction B2c was subjected to flash chromatography (CHCl₃–EtOAc, 95:5) to give compounds **6** (363.6 mg), **7** (371.1 mg), and **10** (26.9 mg). CC of fraction C eluted with hexane–EtOAc, 7:3 and 6:4, gave C1 (5.55 g) and C2 (22.6 g). Fraction C1 was purified by CC eluted with CHCl₃–EtOAc, 95:5, to obtain **4** (2.26 g). Fraction C2 was submitted to CC eluted with hexane–EtOAc, 4:1 (C2a, 0.81 g), 7:3 (C2b, 2.19 g), and 4:6 (C2c, 19.68 g). Compound **4** (726.3 mg) was obtained from fraction C2a. Fraction C2b was purified by CC on bentonitic clay

to obtain 473.7 mg of 4 eluted with hexane–EtOAc, 7:3, and 449.8 mg of 5 eluted with hexane–EtOAc, 6:4. Fractions C2c1 (2.69 g), C2c2 (8.77 g), and C2c3 (3.25 g) were eluted, respectively, with hexane–EtOAc, 3:2, 2:3, and 7:3, from a bentonitic clay CC of fraction C2c. Fraction C2c1 was purified by bentonitic clay CC eluted with hexane–EtOAc, 3:1 (C2c1a), 7:3 (C2c1b), and 3:7 (C2c1c). Fraction C2c1a gave compound 4 (307 mg). Fraction C2c1b was purified by successive CCs eluted with hexane–EtOAc, 3:1, and CHCl₃–EtOAc, 19:1, to obtain compound 1 (17.9 mg). Compounds 2 (34.9 mg) and 5 (477.7 mg) were obtained after two successive CCs of fraction C2c1c (hexane–EtOAc, 7:3; hexane–EtOAc, 19:1). Silica gel CC of fraction C2c2 (CHCl₃–EtOAc, 19:1) gave 8 (650.4 mg), while CC of fraction C2c3 (CHCl₃–EtOAc, 19:1) gave 225.5 mg of 6 and the mixture of compounds 1, 6, and 8, which were purified by CC eluted with hexane–EtOAc mixtures of increasing polarity; 82.2 mg of 1, 69.4 mg of 6, and 55.9 mg of 8 were obtained. 5,6,3'-Trihydroxy-7,4'-dimethoxyflavone (492 mg) was obtained by crystallization (MeOH) from fraction D. Its mother liquors were purified by CC eluted with hexane–EtOAc, 3:2 and 2:3, to obtain fractions D1 and D2, respectively. Fraction D1 (11.3 g) was subjected to CC on bentonitic clay using hexane–EtOAc, 3:2 and 2:3, to obtain D1a and D1b. Silica gel CC (CHCl₃–EtOAc, 9:1) of D1b yielded 3 (34.5 mg).

Tehuainin A (1): colorless crystals (Me₂CO–hexane); mp 240–242 °C; $[\alpha]_D^{25}$ –56.4 (*c* 0.11, Me₂CO); UV (MeOH) λ_{\max} (log ϵ) 207 (3.91), 307 (2.88) nm; IR (KBr) ν_{\max} 1772, 1747, 1504, 895 cm⁻¹; ¹H and ¹³C NMR (CDCl₃) see Table 1; FABMS *m/z* 357 [M + H]⁺; HRFABMS *m/z* 357.1330 (calcd for C₂₀H₂₁O₆, 357.1338).

X-ray Single-Crystal Structure Determination of 1 (ref 18).

Crystal data were collected from a colorless block (0.314 × 0.184 × 0.082 mm) at 298(2) K: C₂₀H₂₁O₆, MW = 356.36, monoclinic, space group P2₁, unit cell dimensions *a* = 7.344(2) Å, *b* = 12.490(3) Å, *c* = 8.907(2) Å, $\alpha = \gamma = 90^\circ$, $\beta = 90.641(5)^\circ$; *V* = 817.0(4) Å³, *Z* = 2, *D_c* = 1.449 Mg/m³, *F*(000) = 376. A total of 2036 reflections were collected in the range 2.29° < θ < 27.89°, with 2036 independent reflections [*R*(int) = 0.0637]; completeness to θ_{\max} was 99.5%. The structure was solved by direct methods and refined by full-matrix least-squares on *F*², with anisotropic temperature factors for non-hydrogen atoms converging at final *R* indices [*I* > 2 σ (*I*)], *R*₁ = 0.0513, *wR*₂ = 0.1114; *R* indices (all data), *R*₁ = 0.0700, *wR*₂ = 0.1190.

Tehuainin B (2): amorphous powder; $[\alpha]_D^{25}$ –40.8 (*c* 0.24, Me₂CO); UV (MeOH) λ_{\max} (log ϵ) 212 (4.10) nm; IR (film) ν_{\max} 1750, 1505, 875 cm⁻¹; ¹H and ¹³C NMR (CDCl₃) see Table 1; EIMS *m/z* 356 [M]⁺ (6); HRFABMS *m/z* 357.1335 (calcd for C₂₀H₂₁O₆, 357.1338).

Tehuainin C (3): amorphous powder; $[\alpha]_D^{25}$ –50.0 (*c* 0.21, MeOH); UV (MeOH) λ_{\max} (log ϵ) 212 (3.36), 265 (2.53) nm; IR (film) ν_{\max} 3497, 1754, 1505, 875 cm⁻¹; ¹H and ¹³C NMR (CDCl₃) see Table 1; EIMS *m/z* 372 [M]⁺ (14); HRFABMS *m/z* 373.1281 (calcd for C₂₀H₂₁O₇, 373.1287).

Acetyltehuainin C (3a). A solution of 3 (17.4 mg, 0.05 mmol) in pyridine (0.2 mL) and Ac₂O (0.2 mL) was stirred for 24 h at 50 °C. The reaction mixture was worked up as usual to obtain a residue, which was purified by CC (hexane–EtOAc, 3:2) to give 4.5 mg (23%) of 3a as an amorphous solid: ¹H and ¹³C NMR (CDCl₃) see Table 1; HRFABMS *m/z* 415.1394 (calcd for C₂₂H₂₃O₈, 415.1393).

Tehuainin D (4): colorless crystals (Me₂CO–hexane); mp 224–226 °C; $[\alpha]_D^{25}$ –174 (*c* 0.15, MeOH); UV (MeOH) λ_{\max} (log ϵ) 209 (3.93), 266 (3.90), 273 (3.89) nm; IR (KBr) ν_{\max} 3432, 3148, 1757, 1718, 1505, 872 cm⁻¹; ¹H and ¹³C NMR (CDCl₃) see Tables 2 and 3; EIMS *m/z* 356 [M]⁺ (16); HRFABMS *m/z* 357.1335 (calcd for C₂₀H₂₁O₆, 357.1338).

Tehuainin E (5): colorless crystals (EtOAc–hexane); mp 247–249 °C; $[\alpha]_D^{25}$ –30 (*c* 0.13, MeOH); UV (MeOH) λ_{\max} (log ϵ) 210 (3.97) nm; IR (KBr) ν_{\max} 3428, 3150, 1757, 1718, 1504, 875 cm⁻¹; ¹H and ¹³C NMR (CDCl₃+ DMSO-*d*₆) see Tables 2 and 3; EIMS *m/z* 372 [M]⁺ (5); HRFABMS *m/z* 373.1282 (calcd for C₂₀H₂₁O₇, 373.1287).

X-ray Single-Crystal Structure Determination of 5 (ref 18).

Crystal data were collected from a colorless prism (0.314 × 0.228 × 0.218 mm) at 298(2) K: C₂₀H₂₁O₇, MW = 372.36, orthorhombic, space group P2₁2₁2₁, unit cell dimensions *a* = 7.163(1) Å, *b* =

15.233(2) Å, *c* = 15.892(3) Å, *V* = 1734.1(5) Å³, *Z* = 4, *D_c* = 1.426 Mg/m³, *F*(000) = 784. A total of 11 482 reflections were collected in the range 1.85° < θ < 27.89°, with 2371 independent reflections [*R*(int) = 0.0548]; completeness to θ_{\max} was 99.8%. The structure was solved by direct methods and refined by full-matrix least-squares on *F*², with anisotropic temperature factors for non-hydrogen atoms converging at final *R* indices [*I* > 2 σ (*I*)], *R*₁ = 0.0545, *wR*₂ = 0.1110; *R* indices (all data), *R*₁ = 0.0768, *wR*₂ = 0.1205.

Tehuainin F (6): colorless crystals (MeOH–H₂O); mp 206–208 °C; $[\alpha]_D^{25}$ –93.9 (*c* 0.23, Me₂CO); UV (MeOH) λ_{\max} (log ϵ) 210 (4.02) nm; IR (KBr) ν_{\max} 3519, 1767, 1731, 1678, 1512, 871 cm⁻¹; ¹H and ¹³C NMR (CDCl₃) see Tables 2 and 3; EIMS *m/z* 372 [M]⁺ (18); HRFABMS *m/z* 373.1288 (calcd for C₂₀H₂₁O₇, 373.1287).

16-Bromotehuainin F (6a). A 0.2 mL (0.16 mmol) amount of a solution of bromine (0.2 mL) in CH₂Cl₂ (5.0 mL) was dropwise added to a stirred solution of 6 (35.4 mg, 0.095 mmol) in CH₂Cl₂ (10 mL) at 0 °C, under N₂. The reaction mixture was kept at 0 °C for 1 h, then at room temperature for 1 h. The reaction was washed with saturated NaHCO₃ (3 × 5 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to yield an oil, which was purified by silica gel CC (CHCl₃/AcOEt, 9:1) to give 8.5 mg (19.8%) of 6a as colorless crystals (EtOAc/hexane): mp 230–232 °C; ¹H NMR (CDCl₃, 500 MHz) δ 7.48 (1H, d, *J* = 2.5 Hz, H-15), 6.50 (1H, d, *J* = 2.5 Hz, H-14), 6.41 (1H, m, H-3), 5.65 (1H, d, *J* = 7.5 Hz, H-19_{pro-R}), 5.16 (1H, dd, *J* = 10.5, 7.5 Hz, H-12), 4.68 (1H, m, H-7), 4.13 (1H, br s), 3.93 (1H, dd, *J* = 7.5, 2.5 Hz, H-19_{pro-S}), 3.52 (1H, br s, H-1), 3.10 (1H, d, *J* = 3.0 Hz, H-8), 2.95 (1H, ddd, *J* = 21.0, 3.0, 1.5 Hz, H-2a), 2.74 (1H, ddd, *J* = 21.0, 4.0, 2.5 Hz, H-2b), 2.42 (1H, dd, *J* = 14.0, 2.5 Hz, H-6 α), 2.08 (1H, dd, *J* = 13.5, 7.5 Hz, H-11 β), 2.00 (1H, ddd, *J* = 14.0, 3.5, 2.0 Hz, H-6 β), 1.43 (1H, dd, *J* = 13.5, 10.5 Hz, H-11 α), 1.42 (3H, s, H-20); ¹³C NMR (CDCl₃, 125 MHz) δ 174.1 (C, C-17), 168.7 (C, C-18), 145.3 (CH, C-15), 134.2 (C, C-4), 127.7 (CH, C-3), 122.5 (C, C-13), 121.6 (C, C-16), 111.0 (CH, C-14), 73.3 (CH₂, C-19), 71.3 (CH, C-12), 66.3 (CH, C-7), 63.9 (C, C-10), 57.6 (CH, C-14), 48.4 (CH, C-8), 43.1 (C, C-5), 39.8 (C, C-9), 37.3 (CH₂, C-11), 3.43 (CH₂, C-6), 27.5 (CH₂, C-2), 23.7 (CH₃, C-20); HRFABMS *m/z* 451.0398 (calcd for C₂₀H₂₀O₇⁷⁹Br, 451.0392).

X-ray Single-Crystal Structure Determination of 6a (ref 18).

Crystal data were collected from a colorless prism (0.458 × 0.092 × 0.062 mm) at 298(2) K: C₂₀H₁₉BrO₇, MW = 451.26, orthorhombic, space group P2₁2₁2₁, unit cell dimensions *a* = 7.503(1) Å, *b* = 8.168(2) Å, *c* = 31.10(1) Å, *V* = 1906.2(6) Å³, *Z* = 4, *D_c* = 1.572 Mg/m³, *F*(000) = 920. A total of 13 237 reflections were collected in the range 2.58° < θ < 25.34°, with 3473 independent reflections [*R*(int) = 0.0735]; completeness to θ_{\max} was 99.8%. The structure was solved by direct methods and refined by full-matrix least-squares on *F*², with anisotropic temperature factors for non-hydrogen atoms converging at final *R* indices [*I* > 2 σ (*I*)], *R*₁ = 0.0579, *wR*₂ = 0.1381; *R* indices (all data), *R*₁ = 0.1120, *wR*₂ = 0.1636.

Tehuainin G (7): colorless crystals (EtOAc–hexane); mp 180–182 °C; $[\alpha]_D^{25}$ –76 (*c* 0.18, MeOH); UV (MeOH) λ_{\max} (log ϵ) 210 (4.25) nm; IR (KBr) ν_{\max} 3409, 1759, 1718, 1505, 873 cm⁻¹; ¹H and ¹³C NMR (CDCl₃) see Tables 2 and 3; EIMS *m/z* 372 [M]⁺ (0.2); HRFABMS *m/z* 373.1285 (calcd for C₂₀H₂₁O₇, 373.1287).

Tehuainin H (8): colorless crystals (EtOAc–hexane); mp 243–245 °C; $[\alpha]_D^{25}$ –58.5 (*c* 0.13, Me₂CO); UV (MeOH) λ_{\max} (log ϵ) 210 (4.05) nm; IR (KBr) ν_{\max} 3397, 1772, 1708, 1501, 874 cm⁻¹; ¹H and ¹³C NMR (CDCl₃) see Tables 2 and 3; FABMS *m/z* 357 [M + H]⁺; HRFABMS *m/z* 357.1347 (calcd for C₂₀H₂₁O₆, 357.1338).

Cytotoxicity Assay. Cytotoxic activity was evaluated by the sulforhodamine B method (SRB), following protocols established by the NCI.¹⁵ All the isolates were screened *in vitro* against six human cancer cell lines: HCT-15 (colorectal adenocarcinoma), K-562 (chronic myelogenous leukemia), MCF-7 (mammary adenocarcinoma), PC-3 (prostatic adenocarcinoma), U-251 (glioblastoma), and SKLU-1 (lung adenocarcinoma) cell lines, supplied by the National Cancer Institute (NCI, USA). Cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10 000 units/mL penicillin G sodium, 10 000 μ g mL⁻¹ streptomycin sulfate, 25 μ g mL⁻¹ amphotericin B (Gibco), and 1%

nonessential amino acids (Gibco). Cells were maintained at 37 °C in a humidified atmosphere with 5% CO₂. Viability of the cells used in the experiments exceeded 95%, as determined by the trypan blue assay. The cells were removed from the tissue culture flasks by treatment with trypsin and diluted with fresh media. Cell suspensions (100 µL, containing 5000 or 7500 cells per well) were placed into 96-well microtiter plates (Costar) and incubated at 37 °C for 24 h in a 5% CO₂ atm. A 100 µL aliquot of the test compounds at concentrations ranging from 1 × 10⁻³ to 50 µM was added to each well. Camptothecin was used as reference. The cultures were exposed to the drug for 48 h. After the incubation period, cells were fixed by addition of 50 µL of cold 50% aqueous trichloroacetic acid. The plates were incubated at 4 °C for 1 h, washed with tap H₂O, and air-dried. The cells were stained with 0.4% SRB, washed with 1% aqueous acetic acid, and air-dried. Bound dye was solubilized with 10 mM unbuffered Tris base (pH 10.5, 100 µL). The plates were placed on a shaker for 5 min, and the absorption was determined at 515 nm using an ELISA plate reader (Bio-Tex Instruments).

Anti-inflammatory Activity. Anti-inflammatory activity was evaluated in the 12-*O*-tetradecanoylphorbol 13-acetate (TPA)-induced ear edema model as previously described.¹⁶ Groups of five male CD-1 mice weighing 25–30 g (in accord with the Mexican official norm MON-062-Z00-1999) were anaesthetized with sodium pentobarbital. TPA (2.5 µg) dissolved in EtOH (10 µL) was topically applied to both sides of the right ear of the mice (5 µL each side). The left ear received only EtOH (10 µL). After 10 min, doses of 0.1 to 1.0 µM of the test compounds or indomethacin (reference compound) dissolved in 20 µL of acetone were applied to the right ear (10 µL each side). Control animals received only vehicle (20 µL). Four hours later the animals were sacrificed by cervical dislocation, and a plug (7 mm diameter) was removed from each ear. The swelling was assessed as the difference in weight between the left and the right ear. The percent of inhibition was calculated by the following equation: % = [(A - B) / A]100; A = edema induced by TPA; B = edema induced by TPA plus sample. Data were analyzed by the one-way analysis of variance (ANOVA) followed by Dunnett's test. The IC₅₀ values were estimated from the linear regression equation.

■ ASSOCIATED CONTENT

● Supporting Information

1D and 2D NMR spectra of compounds 1–8, 3a, 6a, and 11, together with ¹H and ¹³C NMR data of compound 9, are available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: +52-55-5622-4412. Fax: +52-55-5622-2217. E-mail: ahortega@unam.mx.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors thank Dr. A. Toscano for the X-ray crystallographic analyses. The authors are grateful to T. Ramírez-Apan and A. Nieto-Camacho for the biological determinations. The authors also acknowledge H. Rios, R. Gaviño, I. Chávez, B. Quiroz, A. Peña, E. Huerta, R. Patiño, E. García, C. Márquez, L. Velasco, and J. Pérez for the determination of optical rotations and NMR, UV, IR, and MS spectra. E.B. thanks CONACyT for a graduate student scholarship.

■ REFERENCES

- (1) (a) Domínguez, V. G.; Berlin, B.; Castro, R. A. E.; Estrada, L. E. I. *J. Anales del Instituto de Biología*; Universidad Nacional Autónoma de México, 2002; Serie Botánica, Vol. 73, pp 39–80. (b) Kamatou, G. P.; Makunga, N. P.; Ramogola, W. P. N.; Viljoen, A. M. *J. Ethnopharmacol.* **2008**, *119*, 664–672.
- (2) (a) Aguilar, A.; Camacho, J. R.; Chino, S.; Jácquez, P.; López, M. E. *Herbario Medicinal del Instituto Mexicano del Seguro Social*; IMSS: México, 1994; pp 107–110. (b) *Atlas de las Plantas de la Medicina Tradicional Mexicana*; Argueta, V. A., Ed.; Instituto Nacional Indigenista: México, 1994; Vol. I, p 398.
- (3) Topçu, G.; Türkmen, Z.; Ulubelen, A.; Schilling, J. K.; Kingston, D. G. I. *J. Nat. Prod.* **2004**, *67*, 118–121.
- (4) Gödkil, G.; Topçu, G.; Sönmez, U.; Ulubelen, A. *Phytochemistry* **1997**, *46*, 799–800.
- (5) Moghaddam, F. M.; Farimani, M. M.; Seirafi, M.; Taheri, S.; Khavasi, H. R.; Sendker, J.; Proksch, P.; Wray, V.; Edrada, R. *J. Nat. Prod.* **2010**, *73*, 1601–1605.
- (6) (a) Rodríguez-Hahn, L.; Cárdenas, J. In *Current Topics in Phytochemistry*; Asakawa, Y.; Gottlieb, O. R.; Hostettmann, K.; Towers, G. H. N.; Wagner, H.; Waterman, P. G., Eds.; Research Trends: Trivandrum, 1999; Vol. 2, pp 91–101. (b) Ortega, A.; Cárdenas, J.; Toscano, A.; Maldonado, E.; Aumelas, A.; Van Calsteren, M. R.; Jankowski, C. *Phytochemistry* **1991**, *30*, 3357–3360. (c) Wu, S. J.; Chan, H. H.; Hwang, T. L.; Qian, K.; Morris-Natschke, S.; Lee, K. H.; Wu, T. S. *Tetrahedron Lett.* **2010**, *51*, 4287–4290. (d) Aoyagi, Y.; Yamazaki, A.; Kato, R.; Tobe, F.; Fukaya, H.; Nishikawa, T.; Nakahashi, A.; Miura, N.; Monde, K.; Takeya, K. *Tetrahedron Lett.* **2011**, *52*, 1851–1853.
- (7) (a) Xu, G.; Yang, J.; Wang, Y. Y.; Peng, L. Y.; Yang, X. W.; Pan, Z. H.; Liu, E. D.; Li, Y.; Zhao, Q. S. *J. Agric. Food Chem.* **2010**, *58*, 12157–12161. (b) Aoyagi, Y.; Yamazaki, A.; Nakatsugawa, C.; Fukaya, H.; Takeya, K.; Kawauchi, S.; Izumi, H. *Org. Lett.* **2008**, *10*, 4429–4432.
- (8) (a) Calzada, F.; Yepez-Mulia, L.; Tapia-Contreras, A.; Bautista, E.; Maldonado, E.; Ortega, A. *Phytother. Res.* **2010**, *24*, 662–665. (b) Sanchez, A. M.; Jimenez-Ortiz, V.; Sartor, T.; Tonn, C. E.; Garcia, E. E.; Nieto, M.; Burgos, M. H.; Sosa, M. A. *Acta Trop.* **2006**, *98*, 118–124.
- (9) Bisio, A.; Damonte, G.; Fraternali, D.; Giacomelli, E.; Salis, A.; Romussi, G.; Cafaggi, S.; Ricci, D.; De Tommasi, N. *Phytochemistry* **2011**, *72*, 265–275.
- (10) (a) Roth, B. L.; Baner, K.; Westkaemper, R.; Siebert, D.; Rice, K. C.; Steinberg, S.; Ernsberger, P.; Rothman, R. B. *Proc. Natl. Acad. Sci. U. S. A.* **2002**, *99*, 11934–11939. (b) Prisinzano, T. E.; Rothman, R. B. *Chem. Rev.* **2008**, *108*, 1732–1743.
- (11) Ortega, A.; Blount, J. F.; Manchand, P. S. *J. Chem. Soc., Perkin Trans. 1* **1982**, 2505–2508.
- (12) Despite some differences in the assignment of the NMR signals of compound 9, it was identified as 1,10-dehydrosalviarin, a neoclerodane diterpene previously isolated from *Salvia lineata*.¹³ A complete assignment of the ¹H and ¹³C NMR signals of this compound is given as Supporting Information.
- (13) Esquivel, B.; Cárdenas, J.; Ramamoorthy, T. P.; Rodríguez-Hann, L. *Phytochemistry* **1986**, *25*, 2381–2384.
- (14) Nagao, T.; Abe, F.; Kinjo, J.; Okabe, H. *Biol. Pharm. Bull.* **2002**, *25*, 875–879.
- (15) (a) Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. *J. Natl. Cancer Inst.* **1990**, *82*, 1107–1112. (b) Reyes-Gutiérrez, P. E.; Camacho, J. R.; Ramírez-Apan, Ma. T.; Osornio, Y. M.; Martínez, R. *Org. Biomol. Chem.* **2010**, *8*, 4374–4382.
- (16) (a) Merlos, M.; Gómez, L. A.; Giral, M.; Vericat, M. L.; García-Rafanell, J.; Forn, J. *Br. J. Pharmacol.* **1991**, *104*, 990–994. (b) Arciniegas, A.; Pérez-Castorena, A. L.; Nieto-Camacho, A.; Villaseñor, J. L.; Romo de Vivar, A. *J. Mex. Chem. Soc.* **2009**, *53*, 229–232.
- (17) Cabrera, A.; Peón, J.; Velasco, L.; Miranda, R.; Salmón, A.; Salmón, M. *J. Mol. Catal. A* **1995**, *104*, L5–L7.
- (18) Crystallographic data for the structures of compounds 1, 5, and 6a reported in this paper have been deposited with the Cambridge Crystallographic Data Centre, under reference numbers CCDC 878299, 878300, and 878301, respectively. Copies of the data can be obtained, free of charge, on application to the Director, CCDC, 12

Union Road, Cambridge CB2 1EZ, UK (fax: +44-(0)1223-336033 or
e-mail: deposit@ccdc.cam.ac.uk).